Roche

Pacific Biosciences, Roche ink agreement for clinical diagnostics

Friday, September 27, 2013 10:43 AM

Pacific Biosciences of California, provider of the PacBio RS II DNA Sequencing System, has entered into an agreement with Roche Diagnostics to develop diagnostic products, including sequencing systems and consumables, based on Pacific Biosciences' Single Molecule, Real-Time (SMRT) technology.

More... »

Advanced Biological Laboratories, Roche Diagnostics collaborate

Wednesday, September 11, 2013 01:45 PM

Advanced Biological Laboratories (ABL) has signed a non-exclusive collaboration agreement with Roche Diagnostics International for Europe, Middle East, Africa (EMEA) and Latin America (LATAM) territories.

More... »

Roche, Inovio Pharmaceuticals partner

Wednesday, September 11, 2013 01:35 PM

Roche and Inovio Pharmaceuticals have entered into an exclusive worldwide license agreement to research, develop and commercialize Inovio's multi-antigen DNA immunotherapies targeting prostate cancer and hepatitis B. The licensed compounds are currently in preclinical development.

More... »

Heidelberg Pharma, Roche ink license agreement

Wednesday, September 4, 2013 03:57 PM

Germany-based Heidelberg Pharma, a wholly owned subsidiary of Wilex, has signed a license agreement with Roche covering the development of a novel class of antibody drug conjugates (ADCs) based on Heidelberg Pharma’s patented technology to couple α-Amanitin to antibodies. The license agreement covers initial joint research to apply this technology to multiple Roche antibodies towards the identification of development candidates with favorable efficacy/safety profiles.

More... »

Roche, Chugai’s schizophrenia drug forecast to earn $1.5b in 2022

Wednesday, August 28, 2013 12:43 PM

Decision Resources, a research and advisory firms for pharmaceutical and healthcare issues, has found Roche/Chugai’s glycine transporter-1 inhibitor bitopertin is poised to be the first approved treatment to address negative symptoms in schizophrenia following its forecasted launch in the U.S. and Europe in 2016 and in Japan in 2017. As a first-in-class agent for the treatment of these prominent yet underserved symptoms of schizophrenia, Decision Resources expects bitopertin will garner nearly $1.5 billion in major-market sales in 2022.

More... »

Decision Resources suggests breast cancer market to reach $15B by 2022

Friday, August 23, 2013 11:39 AM

Decision Resources, a research and advisory firms for pharmaceutical and healthcare issues, finds that the uptake of premium-priced agents will fuel 5% annual growth in the breast cancer market, with sales reaching more than $15 billion in 2022 in the U.S., France, Germany, Italy, Spain, the U.K. and Japan.

More... »

PTC Therapeutics announces milestone in SMA collaboration

Tuesday, August 13, 2013 10:00 AM

PTC Therapeutics has announced the selection of a development candidate in its spinal muscular atrophy (SMA) collaboration with Roche and the SMA Foundation. The achievement of the milestone triggers a $10 million payment to PTC from Roche.

More... »

Roche launches GS FLX+ System software update

Monday, August 12, 2013 03:37 PM

Roche has launched a software update that extends the range of amplicon lengths available for targeted next-generation sequencing studies on the 454 GS FLX+ System. The latest software enables sequencing of amplicons up to 800bp while maintaining >99% accuracy over the length of the read.

More... »

Medicines Patent Pool, Roche sign HIV agreement

Tuesday, August 6, 2013 10:01 AM

The Medicines Patent Pool and Roche have signed an agreement to increase access in 138 developing countries to Roche’s valganciclovir, a key oral medicine to treat cytomegalovirus (CMV), a viral infection that can cause blindness in people with HIV, by making it up to 90% cheaper than current prices. The companies also will enter into licensing and technology transfer negotiations to encourage the development of internationally approved quality generic versions of valganciclovir.

More... »

Chiltern names Andrew Monaghan director, global pharmacovigilance

Friday, July 26, 2013 03:07 PM

Global CRO Chiltern International has appointed Andrew Monaghan, Ph.D., director, global pharmacovigilance. Monaghan will lead the pharmacovigilance team and expand the company’s pharmacovigilance offering.

More... »